학술논문
S109: ACTIVATION OF PYRUVATE KINASE‐R WITH ETAVOPIVAT (FT‐4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS.
Document Type
Article
Author
Source
HemaSphere; Jan2022 Supplement 1, Vol. 6, p5-5, 1p
Subject
Language
ISSN
25729241